
Opinion|Videos|December 5, 2025
Payer and Prior Authorization Barriers
Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
Advertisement
Episodes in this series

Panelists discuss how payer utilization management and prior authorization processes delay therapy initiation and contribute to high abandonment rates.
The paperwork burden discourages prescribers and frustrates patients, often interrupting continuity of care. Panelists highlight that these barriers disproportionately affect lower-income populations and smaller practices.
They recommend policy reforms that balance cost control with clinical flexibility, enabling timely treatment for high-risk individuals.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
2
Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
5





